Scarica l'app Stockscreener
17.42
4.18%
-0.76
Dopo l'orario di chiusura:
17.42
Precedente Chiudi:
$18.18
Aprire:
$18.04
Volume 24 ore:
944.32K
Relative Volume:
0.79
Capitalizzazione di mercato:
$1.83B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-7.9543
EPS:
-2.19
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
-16.77%
1M Prestazione:
+10.39%
6M Prestazione:
-44.31%
1 anno Prestazione:
-57.14%
Intervallo 1D:
$17.33
$18.77
Intervallo di 1 settimana:
$16.82
$21.13
Portata 52W:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
17.42 | 1.83B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus
IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha
Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus
IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com
FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa
Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus
IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan
Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com
Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News
Ideaya Biosciences Inc (IDYA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
IDYA (Ideaya Biosciences Inc) has impressive results - uspostnews.com
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - knoxdaily.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - GuruFocus
Ideaya Biosciences Inc (NASDAQ: IDYA) Stock Forecast: An Analysis - Marketing Sentinel
IDEAYA Biosciences CEO Fireside Chats: Key Investor Access at Two Major Healthcare Conferences - Stock Titan
Envestnet Asset Management Inc. Sells 11,342 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences Grants Stock Options To New Employees Under 2023 Inducement Plan - Nasdaq
New PARG inhibitors disclosed in Ideaya patent - BioWorld MedTech
IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Analysts review Ideaya Biosciences Inc’s rating - knoxdaily.com
Ideaya Biosciences Inc (IDYA) shows promising results - uspostnews.com
Wells Fargo & Company MN Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event - marketscreener.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC (PR Newswire) - Aktiellt
JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Trading Report - news.stocktradersdaily.com
Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
IDEAYA advances darovasertib in uveal melanoma trial By Investing.com - Investing.com Nigeria
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell - marketscreener.com
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Ph - GuruFocus
IDEAYA advances darovasertib in uveal melanoma trial - Investing.com Australia
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - BioSpace
Ideaya Biosciences Announces Successful FDA Type D Meeting for Darovasertib - MarketScreener
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire) - Aktiellt
Wellington Management Group LLP Has $1.02 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Geode Capital Management LLC Acquires 43,226 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Ideaya Biosciences (IDYA) Launches Expanded Phase 1/2 Trial for IDE397 in Cancer Treatment | GILD Stock News - GuruFocus
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - The Malaysian Reserve
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - marketscreener.com
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and - GuruFocus
Ideaya Biosciences Announces Phase 1/2 Expansion For Ide397 And Trodelvy® Combination In Mtap-Deletion Urothelial Cancer - marketscreener.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):